• Something wrong with this record ?

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition

L. Nobre, M. Zapotocky, V. Ramaswamy, S. Ryall, J. Bennett, D. Alderete, J. Balaguer Guill, L. Baroni, U. Bartels, A. Bavle, M. Bornhorst, DR. Boue, A. Canete, M. Chintagumpala, SL. Coven, O. Cruz, S. Dahiya, P. Dirks, IJ. Dunkel, D. Eisenstat,...

. 2020 ; 4 (-) : . [pub] 20200520

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20022117

PURPOSE: Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS: We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E-mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS: Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (P < .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively (P = .02). CONCLUSION: Use of BRAF inhibition results in robust and durable responses in BRAF V600E-mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas.

2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Aga Khan University Hospital Karachi Pakistan

Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children Toronto ON Canada Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada Department of Pediatric Laboratory Medicine Hospital for Sick Children Toronto ON Canada

Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children Toronto ON Canada Division of Neurosurgery Hospital for Sick Children Toronto ON Canada

Children's National Health System Washington DC

Department of Hematology and Oncology Hospital for Sick Children Toronto ON Canada

Department of Hematology and Oncology Hospital for Sick Children Toronto ON Canada 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Hematology and Oncology Hospital for Sick Children Toronto ON Canada Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children Toronto ON Canada

Department of Hematology and Oncology Hospital for Sick Children Toronto ON Canada Developmental and Stem Cell Biology Program Hospital for Sick Children Toronto ON Canada Department of Medical Biophysics University of Toronto Toronto ON Canada

Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada

Developmental and Stem Cell Biology Program Hospital for Sick Children Toronto ON Canada Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children Toronto ON Canada Division of Neurosurgery Hospital for Sick Children Toronto ON Canada Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada Department of Surgery University of Ontario Toronto ON Canada Department of Medical Biophysics University of Toronto Toronto ON Canada

Division of Pediatric Hematology and Oncology Department of Pediatrics Indiana University Indianapolis IN

G Gaslini Children's Hospital Genoa Italy

Hopp Children's Cancer Center Heidelberg Heidelberg Germany

Hospital Infantil Universitario Niño Jesús Madrid Spain

Hospital Infantil Virgen del Rocío Sevilla Spain

Hospital of Pediatrics SAMIC Prof Dr Juan P Garrahan Buenos Aires Argentina

Hospital Sant Joan de Déu Barcelona Spain

Hospital Universitario y Politecnico La Fe University of Valencia Valencia Spain

Institute d'Hémato Oncologie Pédiatrique Centre Leon Berard Lyon France

Jimmy Everest Section of Pediatric Heamatology Oncology University of Oklahoma Health Sciences Center Oklahoma City OK

Lund University Lund Sweden

Memorial Sloan Kettering Cancer Center New York NY

Nationwide Children's Hospital and Ohio State University Columbus OH

Oslo University Hospital Oslo Norway

Portuguese Oncology Institute Lisbon Portugal

Royal Children's Hospital Murdoch Children's Research Institute University of Melbourne Melbourne VIC Australia

Sahlgrenska University Hospital University of Gothenburg Gothenburg Sweden

Schneiders Children's Medical Center of Israel Petah Tikva Israel

Seattle Children's Hospital Seattle WA

Semmelweis University Budapest Hungary

Stollery Children's Hospital University of Alberta Edmonton AB Canada

Texas Children's Cancer Center Houston TX

Universite Laval Quebec City QC Canada

University Hospital Brno Masaryk University and ICRC Brno Brno Czech Republic

University of North Carolina at Chapel Hill Chapel Hill NC

Washington University School of Medicine St Louis MO

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022117
003      
CZ-PrNML
005      
20210204112652.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/PO.19.00298 $2 doi
035    __
$a (PubMed)32923898
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nobre, Liana $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
245    10
$a Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition / $c L. Nobre, M. Zapotocky, V. Ramaswamy, S. Ryall, J. Bennett, D. Alderete, J. Balaguer Guill, L. Baroni, U. Bartels, A. Bavle, M. Bornhorst, DR. Boue, A. Canete, M. Chintagumpala, SL. Coven, O. Cruz, S. Dahiya, P. Dirks, IJ. Dunkel, D. Eisenstat, C. Faure Conter, E. Finch, JL. Finlay, D. Frappaz, ML. Garre, K. Gauvain, AG. Bechensteen, JR. Hansford, I. Harting, P. Hauser, LN. Hazrati, A. Huang, SG. Injac, V. Iurilli, M. Karajannis, G. Kaur, M. Kyncl, L. Krskova, N. Laperriere, V. Larouche, A. Lassaletta, S. Leary, F. Lin, S. Mascelli, T. McKeown, T. Milde, A. Morales La Madrid, G. Morana, H. Morse, N. Mushtaq, DS. Osorio, R. Packer, Z. Pavelka, E. Quiroga-Cantero, J. Rutka, M. Sabel, D. Salgado, P. Solano, J. Sterba, J. Su, D. Sumerauer, MD. Taylor, H. Toledano, DS. Tsang, M. Valente Fernandes, F. van Landeghem, CM. van Tilburg, B. Wilson, O. Witt, J. Zamecnik, E. Bouffet, C. Hawkins, U. Tabori,
520    9_
$a PURPOSE: Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS: We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E-mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS: Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (P < .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively (P = .02). CONCLUSION: Use of BRAF inhibition results in robust and durable responses in BRAF V600E-mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zapotocky, Michal $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada. Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Ramaswamy, Vijay $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada. Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, ON, Canada. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
700    1_
$a Ryall, Scott $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Bennett, Julie $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Alderete, Daniel $u Hospital of Pediatrics SAMIC Prof. Dr Juan P. Garrahan, Buenos Aires, Argentina.
700    1_
$a Balaguer Guill, Julia $u Hospital Universitario y Politecnico La Fe, University of Valencia, Valencia, Spain.
700    1_
$a Baroni, Lorena $u Hospital of Pediatrics SAMIC Prof. Dr Juan P. Garrahan, Buenos Aires, Argentina.
700    1_
$a Bartels, Ute $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Bavle, Abhishek $u Jimmy Everest Section of Pediatric Heamatology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
700    1_
$a Bornhorst, Miriam $u Children's National Health System, Washington, DC.
700    1_
$a Boue, Daniel R $u Nationwide Children's Hospital and Ohio State University, Columbus, OH.
700    1_
$a Canete, Adela $u Hospital Universitario y Politecnico La Fe, University of Valencia, Valencia, Spain.
700    1_
$a Chintagumpala, Murali $u Texas Children's Cancer Center, Houston, TX.
700    1_
$a Coven, Scott L $u Division of Pediatric Hematology and Oncology, Department of Pediatrics, Indiana University, Indianapolis, IN.
700    1_
$a Cruz, Ofelia $u Hospital Sant Joan de Déu, Barcelona, Spain.
700    1_
$a Dahiya, Sonika $u Washington University School of Medicine, St Louis, MO.
700    1_
$a Dirks, Peter $u Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada. Division of Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Dunkel, Ira J $u Memorial Sloan Kettering Cancer Center, New York, NY.
700    1_
$a Eisenstat, David $u Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
700    1_
$a Faure Conter, Cecile $u Institute d'Hémato-Oncologie Pédiatrique, Centre Leon Berard, Lyon, France.
700    1_
$a Finch, Elizabeth $u University of North Carolina at Chapel Hill, Chapel Hill, NC.
700    1_
$a Finlay, Jonathan L $u Nationwide Children's Hospital and Ohio State University, Columbus, OH.
700    1_
$a Frappaz, Didier $u Institute d'Hémato-Oncologie Pédiatrique, Centre Leon Berard, Lyon, France.
700    1_
$a Garre, Maria Luisa $u G. Gaslini Children's Hospital, Genoa, Italy.
700    1_
$a Gauvain, Karen $u Washington University School of Medicine, St Louis, MO.
700    1_
$a Bechensteen, Anne Grete $u Oslo University Hospital, Oslo, Norway.
700    1_
$a Hansford, Jordan R $u Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, VIC, Australia.
700    1_
$a Harting, Inga $u Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
700    1_
$a Hauser, Peter $u Semmelweis University, Budapest, Hungary.
700    1_
$a Hazrati, Lili-Naz $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
700    1_
$a Huang, Annie $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada. Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Injac, Sarah G $u Texas Children's Cancer Center, Houston, TX.
700    1_
$a Iurilli, Valentina $u G. Gaslini Children's Hospital, Genoa, Italy.
700    1_
$a Karajannis, Matthias $u Memorial Sloan Kettering Cancer Center, New York, NY.
700    1_
$a Kaur, Gurcharanjeet $u Memorial Sloan Kettering Cancer Center, New York, NY.
700    1_
$a Kyncl, Martin $u Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Krskova, Lenka $u Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Laperriere, Normand $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Larouche, Valerie $u Universite Laval, Quebec City, QC, Canada.
700    1_
$a Lassaletta, Alvaro $u Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
700    1_
$a Leary, Sarah $u Seattle Children's Hospital, Seattle, WA.
700    1_
$a Lin, Frank $u Texas Children's Cancer Center, Houston, TX.
700    1_
$a Mascelli, Samantha $u G. Gaslini Children's Hospital, Genoa, Italy.
700    1_
$a McKeown, Tara $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Milde, Till $u Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
700    1_
$a Morales La Madrid, Andres $u Hospital Sant Joan de Déu, Barcelona, Spain.
700    1_
$a Morana, Giovanni $u G. Gaslini Children's Hospital, Genoa, Italy.
700    1_
$a Morse, Helena $u Lund University, Lund, Sweden.
700    1_
$a Mushtaq, Naureen $u Aga Khan University Hospital, Karachi, Pakistan.
700    1_
$a Osorio, Diana S $u Nationwide Children's Hospital and Ohio State University, Columbus, OH.
700    1_
$a Packer, Roger $u Children's National Health System, Washington, DC.
700    1_
$a Pavelka, Zdenek $u University Hospital Brno, Masaryk University, and ICRC Brno, Brno, Czech Republic.
700    1_
$a Quiroga-Cantero, Eduardo $u Hospital Infantil Virgen del Rocío, Sevilla, Spain.
700    1_
$a Rutka, James $u Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada. Division of Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Sabel, Magnus $u Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
700    1_
$a Salgado, Duarte $u Portuguese Oncology Institute, Lisbon, Portugal.
700    1_
$a Solano, Palma $u Hospital Infantil Virgen del Rocío, Sevilla, Spain.
700    1_
$a Sterba, Jaroslav $u University Hospital Brno, Masaryk University, and ICRC Brno, Brno, Czech Republic.
700    1_
$a Su, Jack $u Texas Children's Cancer Center, Houston, TX.
700    1_
$a Sumerauer, David $u Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Taylor, Michael D $u Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, ON, Canada. Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada. Division of Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Department of Surgery, University of Ontario, Toronto, ON, Canada. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
700    1_
$a Toledano, Helen $u Schneiders Children's Medical Center of Israel, Petah Tikva, Israel.
700    1_
$a Tsang, Derek S $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Valente Fernandes, Mariana $u Portuguese Oncology Institute, Lisbon, Portugal.
700    1_
$a van Landeghem, Frank $u Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
700    1_
$a van Tilburg, Cornelis M $u Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
700    1_
$a Wilson, Bev $u Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
700    1_
$a Witt, Olaf $u Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
700    1_
$a Zamecnik, Josef $u Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Bouffet, Eric $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Hawkins, Cynthia $u Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, ON, Canada.
700    1_
$a Tabori, Uri $u Department of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada. Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
773    0_
$w MED00204957 $t JCO precision oncology $x 2473-4284 $g Roč. 4, č. - (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32923898 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20210204112650 $b ABA008
999    __
$a ind $b bmc $g 1591824 $s 1112789
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 4 $c - $e 20200520 $i 2473-4284 $m JCO precision oncology $n JCO Precis Oncol $x MED00204957
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Logged in users only

Archiving options